Kyle Malady
Known title: EVP and Group CEO-VZ BusinessCIK: 0001760581
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
Transaction History
| VZ | ▼ Sell | Open Market | 1,100 | $50K | 10/6/2026 | View on chart |
| VZ | ▼ Sell | Open Market | 1,100 | $51K | 9/29/2026 | View on chart |
| VZ | ▼ Sell | Open Market | 1,100 | $52K | 9/22/2026 | View on chart |
| VZ | ▼ Sell | Open Market | 1,100 | $56K | 9/15/2026 | View on chart |
| VZ | ▼ Sell | Open Market | 1,100 | $55K | 9/8/2026 | View on chart |
| VZ | ▼ Sell | Open Market | 1,100 | $56K | 9/1/2026 | View on chart |
| VZ | ▼ Sell | Open Market | 1,100 | $55K | 8/25/2026 | View on chart |
| VZ | ▼ Sell | Open Market | 1,100 | $54K | 8/18/2026 | View on chart |
| DXCM | ▲ Buy | Grant | 5,575 | $0 | 5/28/2026 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 17,049 | $855K | 2/27/2026 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 17,057 | $855K | 2/27/2026 | View on chart |
| VZ | ▲ Buy | Option Exercise | 34,020 | — | 2/27/2026 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 16,602 | $832K | 2/27/2026 | View on chart |
| VZ | ▲ Buy | Option Exercise | 31,331 | — | 2/27/2026 | View on chart |
| VZ | ▲ Buy | Option Exercise | 34,936 | — | 2/27/2026 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 58,030 | $2.8M | 2/11/2026 | View on chart |
| VZ | ▲ Buy | Grant | 119,409 | — | 2/11/2026 | View on chart |
| DXCM | ▼ Sell | Open Market | 667 | $54K | 9/5/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 9,701 | $425K | 5/8/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 299 | $13K | 5/8/2025 | View on chart |
| DXCM | ▲ Buy | Grant | 5,192 | $0 | 5/8/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 9,000 | $397K | 5/7/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 7,500 | $329K | 4/30/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 10,000 | $430K | 4/24/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 5,000 | $212K | 4/23/2025 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 18,138 | $782K | 3/1/2025 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 15,574 | $671K | 3/1/2025 | View on chart |
| VZ | ▲ Buy | Option Exercise | 32,774 | — | 3/1/2025 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 9,146 | $394K | 3/1/2025 | View on chart |
| VZ | ▲ Buy | Option Exercise | 31,914 | — | 3/1/2025 | View on chart |
| VZ | ▲ Buy | Option Exercise | 19,678 | — | 3/1/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 6,590 | $262K | 2/4/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 8,000 | $319K | 2/3/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 11,085 | $453K | 1/29/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 20,000 | $810K | 1/28/2025 | View on chart |
| VZ | ▼ Sell | Open Market | 20,000 | $811K | 1/27/2025 | View on chart |
| DXCM | ▲ Buy | Grant | 2,613 | $0 | 5/22/2024 | View on chart |
| VZ | ▲ Buy | Option Exercise | 15,085 | — | 3/1/2024 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 7,362 | $296K | 3/1/2024 | View on chart |
| VZ | ▲ Buy | Option Exercise | 18,420 | — | 3/1/2024 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 8,989 | $361K | 3/1/2024 | View on chart |
| VZ | ▲ Buy | Option Exercise | 29,875 | — | 3/1/2024 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 16,555 | $666K | 3/1/2024 | View on chart |
| VZ | ▼ Sell | Open Market | 24,000 | $979K | 2/22/2024 | View on chart |
| VZ | ▼ Sell | Open Market | 15,000 | $605K | 2/15/2024 | View on chart |
| VZ | ▲ Buy | Grant | 9,503 | — | 2/14/2024 | View on chart |
| VZ | ▼ Sell | Tax Withholding | 3,268 | $131K | 2/14/2024 | View on chart |
| DXCM | ▲ Buy | Grant | 2,885 | $3 | 5/18/2023 | View on chart |
| DXCM | ▲ Buy | Grant | 979 | $1 | 5/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Verizon Faces Fixed Wireless Growth and SpaceX Mobile Competition
Verizon is evaluating whether its fixed‑wireless service can grow without hurting mobile profits. Analysts are also watching SpaceX’s new mobile plans, which could shift the competitive landscape for Verizon’s core business. In addition, Starlink’s potential to lower wireless costs could influence Verizon customers’ choices. These developments add uncertainty to Verizon’s future revenue mix.
Verizon Faces Fixed Wireless Growth and SpaceX Mobile Competition. Verizon is evaluating whether its fixed‑wireless service can grow without hurting mobile profits. Analysts are also watching SpaceX’s new mobile plans, which could shift the competitive landscape for Verizon’s core business. In addition, Starlink’s potential to lower wireless costs could influence Verizon customers’ choices. These developments add uncertainty to Verizon’s future revenue mix.